Top Page
Resonance Health Ltd
(Sydney:RHT)
Resonance Health Ltd (RHT) vs. iShares MSCI Australia ETF (EWA)
Resonance Health Ltd Business Overview & Revenue Model
Resonance Health Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.07M | 11.07M | 8.59M | 4.40M | 3.83M | 3.78M |
| Gross Profit | 11.07M | 11.07M | 8.59M | 4.40M | 3.83M | 3.78M |
| EBITDA | -1.41M | -1.41M | -382.00K | -827.69K | -1.34M | 707.69K |
| Net Income | -1.73M | -1.73M | 169.30K | -780.00K | -1.14M | 585.86K |
Balance Sheet | ||||||
| Total Assets | 17.89M | 17.89M | 20.28M | 10.98M | 11.69M | 12.44M |
| Cash, Cash Equivalents and Short-Term Investments | 2.98M | 2.98M | 6.85M | 6.36M | 6.78M | 8.86M |
| Total Debt | 3.80M | 3.80M | 3.70M | 272.94K | 268.22K | 60.10K |
| Total Liabilities | 8.50M | 8.50M | 9.35M | 1.05M | 995.58K | 611.74K |
| Stockholders Equity | 9.39M | 9.39M | 10.93M | 9.94M | 10.69M | 11.83M |
Cash Flow | ||||||
| Free Cash Flow | 805.39K | 805.39K | 1.01M | -624.93K | -1.42M | 772.72K |
| Operating Cash Flow | 1.25M | 1.25M | 1.39M | -157.03K | -712.67K | 1.17M |
| Investing Cash Flow | -4.52M | -4.52M | -3.94M | -467.90K | -704.00K | -395.79K |
| Financing Cash Flow | -649.26K | -649.26K | 3.01M | -81.97K | -107.11K | 1.20M |
Resonance Health Ltd Technical Analysis
Resonance Health Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | AU$15.10M | -3.26 | -27.84% | ― | 6.77% | -8.45% | |
55 Neutral | AU$74.13M | -8.12 | -8647.54% | ― | 25.98% | 22.10% | |
52 Neutral | AU$23.25M | -12.89 | -17.05% | ― | 28.91% | -1050.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$12.18M | -1.43 | ― | ― | -40.05% | -49.57% | |
41 Neutral | AU$43.43M | -9.29 | -81.30% | ― | -36.68% | 79.41% | |
40 Underperform | AU$84.39M | -11.89 | ― | ― | ― | ― |
Resonance Health Ltd Corporate Events
Resonance Health Ltd has announced a change in the director’s interest in securities. Simon Panton, a director of the company, has increased his indirect holdings through entities controlled by him and his wife, acquiring a total of 423,522 ordinary fully paid shares. This change reflects an increase in the director’s stake in the company, potentially signaling confidence in the company’s future performance.
Resonance Health Ltd has announced the cessation of Dr. Martin Peter Blake as a director, effective November 13, 2025. Dr. Blake held significant interests in the company, with 3,798,590 ordinary fully paid shares directly and an additional 2,666,087 shares through a superannuation fund. This change in directorship may impact the company’s governance and strategic direction, given Dr. Blake’s substantial shareholding and involvement.
Resonance Health Ltd announced the results of its Annual General Meeting held on November 13, 2025, where all resolutions were approved by poll. Key resolutions included the re-election of directors and the approval of a 10% placement facility, indicating strong shareholder support and strategic positioning for future growth.
Resonance Health Ltd has announced that its business transformation is well underway, as highlighted in their recent Annual General Meeting. The company reported a normalized operating EBITDA, which accounts for various financial adjustments, indicating a strategic shift in operations. This transformation is expected to impact the company’s financial health and market positioning positively, potentially benefiting stakeholders by improving operational efficiency and financial performance.
Resonance Health Ltd reported a positive net cash flow from operations and significant progress across its business segments, including Resonance Clinical, SaMD, and TrialsWest. The company achieved key milestones in its $13.8M clinical trial services agreement and expanded its SaMD business with new contracts and extensions. The TrialsWest network grew with the opening of a new site, and the company is exploring opportunities in China and India. With a strong sales pipeline and new product offerings, Resonance Health is optimistic about its growth trajectory.
Resonance Health Ltd announced the cessation of 1,706,991 performance rights due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could have implications for its financial strategy and stakeholder interests.
Resonance Health Ltd has announced the application for quotation of 3,747,998 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of an employee incentive scheme, indicating a strategic effort to enhance employee engagement and retention. The issuance of these securities may impact the company’s market positioning by potentially increasing liquidity and shareholder value.
Resonance Health Ltd has announced the details of its 2025 Annual General Meeting (AGM), scheduled for November 13, 2025, in Perth, Western Australia. Shareholders can participate in the AGM in person or by proxy, with specific instructions provided for voting. The company will not send physical copies of the meeting notice to shareholders who have not opted for electronic communication, emphasizing the importance of accessing the notice online. This announcement underscores the company’s commitment to efficient shareholder communication and engagement.
Resonance Health Ltd has announced an investor strategy day, inviting stakeholders to join a live webcast hosted by key company executives. The event aims to provide insights into the company’s strategic direction and will be available for later viewing. This initiative underscores Resonance Health’s commitment to transparency and engagement with its stakeholders, potentially strengthening its market position and fostering investor confidence.
Resonance Health Ltd has announced the appointment of Andrew Harrison as a director, effective October 1, 2025. Harrison holds significant interests in the company, including 8 million ordinary fully paid shares and additional loan shares through a family trust. This appointment and Harrison’s substantial shareholding may influence the company’s strategic direction and stakeholder interests.
Resonance Health Ltd announced significant leadership changes with Dr. Martin Blake retiring as Chair and Non-Executive Director, to be succeeded by Mr. Aaron Brinkworth following the AGM on November 13, 2025. Mr. Andrew Harrison, the current CEO, will also take on the role of Managing Director, reflecting the company’s strategic focus on governance and growth. These changes are expected to strengthen Resonance Health’s position in the healthcare technology industry, as the company continues to expand its portfolio and global reach.